Kras-Specific Autologous Tcr-T Cell
Pancreatic
Corregene Biotechnology Co., LtdCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Pancreatic cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ANTI-PSCA MONOCLONAL ANTIBODY AGS-1C4D4 Agensys, Inc. | Phase 2 | B |
CEFOXITIN Memorial Sloan Kettering Cancer Center | Phase 3 | B |
Olaparib AstraZeneca | Phase 2 | B |
nhs7108 Aimmune Nestlé Health Science US R&D, LLC | Phase 2 | CCC |
Pancrelipase Aimmune Nestlé Health Science US R&D, LLC | Phase 2 | CCC |
View all 15 →
Same molecule, other indications
Kras-Specific Autologous Tcr-T Cell is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →